Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.
These antibodies, described this week in the journal Gastroenterology, “have high potential” for improving diagnosis and treatment of norovirus illness as well as furthering efforts to develop the first effective norovirus vaccine, the researchers concluded.
“In the past no one could grow norovirus in the lab, so progress on developing treatments was slow,” said James Crowe Jr., MD, the paper’s corresponding author. “Here we combined brand-new technologies for growing norovirus in primary human gut tissues with our state-of-the-art antibody discovery platform to identify these exciting antibodies.”
Norovirus is a highly contagious virus that causes vomiting and diarrhea. According to the U.S. Centers for Disease Control and Prevention, about 20 million people get sick from norovirus each year in the United States, most from close contact with infected people or by eating contaminated food.
While most people recover from norovirus illness in one to three days, the infection contributes to approximately 200,000 deaths worldwide each year, mostly among young children and the elderly. Roughly 600 of those deaths occur annually in the United States.
Crowe directs the Vanderbilt Vaccine Center. He and his colleagues have developed innovative technologies for isolating and studying antiviral antibodies, and they have isolated human monoclonal antibodies for many pathogenic viruses, including Zika, HIV, dengue, influenza, Ebola, respiratory syncytial virus (RSV) and rotavirus.
His lab has developed high-efficiency methods that can quickly isolate antibody-producing white blood cells from survivor blood samples. By fusing the white blood cells to fast-growing myeloma (cancer) cells, the researchers can produce large quantities of “monoclonal” antibodies that target specific viruses.
The current study, conducted in collaboration with researchers at Baylor College of Medicine, isolated monoclonal antibodies from patients previously infected with norovirus. The researchers tested the neutralizing capability of the antibodies against live virus grown in a monolayer culture of human cells from the middle segment of the small intestine.
They identified a large panel of human monoclonal antibodies that neutralize the pandemic GII.4 Sydney strain of the virus, which currently is the major circulating norovirus strain associated with human disease. They identified at least three neutralizing sites on the virus that should aid efforts to develop an effective vaccine.
Crowe is the Ann Scott Carell Professor in the Departments of Pediatrics and Pathology, Microbiology and Immunology in the Vanderbilt University School of Medicine.
Graduate student Gabriela Alvarado is the paper’s first author. Others from the Crowe lab who contributed to the paper were Robin Bombardi and Nurgun Kose.
The research was supported in part by National Institutes of Health grants DK056338 and AI057788.
